IP Library › Granted Patent US 12,709,605
Granted Patent B2
US 12,709,605 · App. 18/785,279 · Granted Aug 18, 2026

Pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2

Inventors: Luca Gobbi (Basel, CH); Uwe Grether (Basel, CH); Julian Kretz (Basel, CH); Simon M. Ametamey (Zurich, CH)
Assignees: HOFFMANN-LA ROCHE INC.; ETH ZUERICH
C07D401/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,709,605
App. No.
18/785,279
Filed
Jul 26, 2024
Granted
Aug 18, 2026
Kind
B2
Art Unit
1621
USPC
514/277
Abstract

The invention relates to a compound of formula (I) wherein A 1 , A 2 , X and R 1 -R 3 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.

Claims (20)

1 . A process for the preparation of a compound comprising one of the following steps:

(a) the reaction of a compound of formula (A)

in the presence of R 1 —H, a palladium catalyst and a base;

(b) the reaction of a compound of formula (B)

in the presence of NH 2 —C(R 2 R 3 )-A 2 -O—(CH 2 ) n —(CD 2 ) m -X, a coupling agent and a base, wherein:

R 1 is alkoxyazetidinyl, dihaloazetidinyl or pyrrolidinyl;

R 2 and R 3 are independently selected from hydrogen and alkyl;

A 1 is —CH— or nitrogen;

A 2 is —CH 2 — or carbonyl;

X is halogen;

Y is halogen;

n is 0 to 3; and

m is 0 or 1;

provided that m and n are not both 0 at the same time.

2 . The process of claim 1 , wherein R 1 is methoxyazetidinyl, difluoroazetidinyl or pyrrolidinyl.

3 . The process of claim 1 , wherein R 2 and R 3 are independently selected from hydrogen, ethyl or butyl.

4 . The process of claim 3 , wherein R 2 and R 3 are both ethyl at the same time, or one of R 2 and R 3 is hydrogen and the other one is butyl.

5 . The process of claim 1 , wherein A 1 is —CH—.

6 . The process of claim 1 , wherein X is fluorine.

7 . The process of claim 1 , wherein n is 1, 2 or 3.

Priority Claims (1)
EP 18180137 · Jun 27, 2018 · regional
Continuity (3)
Division 17125650 · Dec 17, 2020
Continuation PCTEP2019066811 · Jun 25, 2019
Related Publication 20240383872A1 · Nov 21, 2024
References Cited (64)
US 9303012B2 · Bendels et al. · 2016 [cited by applicant]
US 9321727B2 · Bissantz et al. · 2016 [cited by applicant]
US 9403808B2 · Bissantz et al. · 2016 [cited by applicant]
US 9409866B2 · Grether et al. · 2016 [cited by applicant]
US 9512141B2 · Dhurwasulu et al. · 2016 [cited by applicant]
US 9522886B2 · Frei et al. · 2016 [cited by applicant]
US 10155942B2 · Kurihara et al. · 2018 [cited by applicant]
US 10308659B2 · Gavelle et al. · 2019 [cited by applicant]
US 10912849B2 · Wu et al. · 2021 [cited by applicant]
US 11479807B2 · Kennedy et al. · 2022 [cited by applicant]
US 11655243B2 · Ametamey et al. · 2023 [cited by applicant]
US 11999710B2 · Ametamey et al. · 2024 [cited by applicant]
US 12071420B2 · Gobbi et al. · 2024 [cited by applicant]
US 20050245544A1 · Bell et al. · 2005 [cited by applicant]
US 20070105861A1 · Lee et al. · 2007 [cited by applicant]
US 20080280868A1 · Eatherton et al. · 2008 [cited by applicant]
US 20200182940A1 · Tsai · 2020 [cited by applicant]
US 20200239490A1 · Frei et al. · 2020 [cited by applicant]
US 20210115011A1 · Gobbi et al. · 2021 [cited by applicant]
US 20210115012A1 · Ametamey et al. · 2021 [cited by applicant]
US 20210115027A1 · Ametamey et al. · 2021 [cited by applicant]
US 20210130334A1 · Ametamey et al. · 2021 [cited by applicant]
CL 2020002927A1 · 2021 [cited by applicant]
CN 1703402A · 2005 [cited by applicant]
CN 101522644A · 2009 [cited by applicant]
CN 103608332A · 2014 [cited by applicant]
CN 104024232A · 2014 [cited by applicant]
CN 104837830A · 2015 [cited by applicant]
CN 104854092A · 2015 [cited by applicant]
CN 106132958A · 2016 [cited by applicant]
CN 106349156A · 2017 [cited by applicant]
CN 106458984A · 2017 [cited by applicant]
CO 6890101A2 · 2014 [cited by applicant]
CO 2017005374A · 2017 [cited by applicant]
ES 2388833T3 · 2012 [cited by applicant]
JP 2014516071A · 2014 [cited by applicant]
JP 2014534210A · 2014 [cited by applicant]
JP 2016501240A · 2016 [cited by applicant]
JP 2017509688A · 2017 [cited by applicant]
RU 2612138C2 · 2017 [cited by applicant]
WO 9504045A1 · 1995 [cited by applicant]
WO 2012168350A1 · 2012 [cited by applicant]
WO 2013060751A1 · 2013 [cited by applicant]
WO 2014086705A1 · 2014 [cited by applicant]
WO 2014086805A1 · 2014 [cited by applicant]
WO 2014086806A1 · 2014 [cited by applicant]
WO 2014086807A1 · 2014 [cited by applicant]
WO 2014154612A1 · 2014 [cited by applicant]
WO 2015150438A1 · 2015 [cited by applicant]
WO 2015150440A1 · 2015 [cited by applicant]
WO 2016066534A1 · 2016 [cited by applicant]
WO 2017097732A1 · 2017 [cited by applicant]
WO 2018234284A1 · 2018 [cited by applicant]
WO 2020002320A1 · 2020 [cited by applicant]
Communication Pursuant to Article 94(3) EPC for European Application No. 19733484.0, mailed on Sep. 23, 2022, 6 pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/EP2019/066799, mailed on Jul. 10, 2019, 11 pages. [cited by applicant]
International Search Report and Written Opinion issued in International Application No. PCT/EP2019/066811, mailed on Aug. 8, 2019, 10 pages. [cited by applicant]
Search Report for Russian Application No. 2021101106/04(002123), mailed on Aug. 23, 2022, 2 pages. [cited by applicant]
Belikov, V.G. (2007) “Pharmaceutical Chemistry”, Moscow: MEDpress-Inform, 13 pages. [cited by applicant]
Haider et al. (2020) “Identification and Preclinical Development of a 2,5,6-Trisubstituted Fluorinated Pyridine Derivative as a Radioligand for the Positron Emission Tomography Imaging of Cannabinoid Type 2 Receptors”, … [cited by applicant]
Haider et al. (2019) “Structure-Activity Relationship Studies of Pyridine-Based Ligands and Identification of a Fluorinated Derivative for Positron Emission Tomography Imaging of Cannabinoid Type 2 Receptors”, Journal o… [cited by applicant]
Pacher et al. (2011) “Is Lipid Signaling Through Cannabinoid 2 Receptors Part of a Protective System?”, Progress in lipid research, 50(2):193-211. [cited by applicant]
Pitt et al. (1975) “The Synthesis of Deuterium, Carbon-14, and Carrier-free Tritium Labeled Cannabinoids”, Journal of Labelled Compounds, 11(4):551-575. [cited by applicant]
Slavik et al. (May 7, 2015) “Discovery of a High Affinity and Selective Pyridine Analog as a Potential Positron Emission Tomography Imaging Agent for Cannabinoid Type 2 Receptor”, Journal of Medicinal Chemistry, 58 (10)… [cited by applicant]